Abstract:

Objective To observe the clinical efficacy of tolvaptan in  treatment of hyponatremia in patients with chronic heart failure(CHF) and to evaluate
its efficacy and safety.Methods 16 patients with CHF and hyponatremia were ran
domly divided into therapy group（conventional treatment + tolvaptan，8 cases) and control group(conventional treatment,8 cases).All the patients were evaluated
 by observing the serum sodium,serum sodium,urine volume and body weight 8 and
 24 h after treatment with double-blind control method,and Minnesota Living with Heart Failure Questionnaire(MLHFQ) was performed  8 d after treatment,and the adverse reactions were observed.Results The levels of serum sodium of the patients in therapy group 8 and 24 h after treatment were
 significantly higher than those in control group (P<0.01).The urine volume of the patients in therapy group 24 h after treatment was increased compared with
 
before treatment (P<0.05),but there was no significant difference between therapy group and control group(P>0.05).The MLHFQ of the patients in two groups 8 d after treatment were significantly improved compared with before treatment(P<0.01),the improvement in therapy group was more significant  compared with control group(P<0.05).There were no adverse events,and only 1 case of dry mouth was found in therapy
 group.Conclusion The efficacy of tolvaptan in treatment of the patients with CHF and hyponatremia is better,and it can improve their qualities of life with
good safety and tolerability.

Key words: chronic heart failure, tolvaptan, hyponatremia